Phase I trial of interleukin-12 in combination with paclitaxel plus Herceptin [trastuzumab] in patients with HER2-positive malignancies.

Trial Profile

Phase I trial of interleukin-12 in combination with paclitaxel plus Herceptin [trastuzumab] in patients with HER2-positive malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Jun 2013

At a glance

  • Drugs Interleukin-12 (Primary) ; Paclitaxel; Trastuzumab
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Jun 2010 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
    • 30 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top